GL

Unveiling Insights on Globe Life Stock

Globe Life shares fell by -15.5% during the day's morning session, and are now trading at a price of $88.62. Is it time to buy the dip? To better answer that question, it's essential to check if the market is valuing the company's shares fairly in terms of its earnings and equity levels.

Globe Life Is Reasonably Valued:

Globe Life Inc., through its subsidiaries, provides various life and supplemental health insurance products, and annuities to lower middle- and middle-income families in the United States. The company belongs to the Finance sector, which has an average price to earnings (P/E) ratio of 12.38 and an average price to book (P/B) ratio of 1.58. In contrast, Globe Life has a trailing 12 month P/E ratio of 8.8 and a P/B ratio of 1.85.

When we divideGlobe Life's P/E ratio by its expected five-year EPS growth rate, we obtain a PEG ratio of 0.61, which indicates that the market is undervaluing the company's projected growth (a PEG ratio of 1 indicates a fairly valued company). Your analysis of the stock shouldn't end here. Rather, a good PEG ratio should alert you that it may be worthwhile to take a closer look at the stock.

A Positive EPS Growth Rate but Not Enough Current Assets to Cover Current Liabilities:

2018 2019 2020 2021 2022 2023
Revenue (M) $4,304 $4,528 $4,738 $4,100 $4,303 $4,456
Interest Income (M) $90 $84 $87 $83 $90 $102
Net Margins 16% 17% 15% 18% 17% 22%
Net Income (M) $701 $761 $732 $745 $740 $971
Depreciation & Amort. (M) $13 $16 $17 $20 $21 $21
Diluted Shares (M) 115 111 107 103 99 96
Earnings Per Share $6.09 $6.83 $6.82 $7.22 $7.47 $10.07
EPS Growth n/a 12.15% -0.15% 5.87% 3.46% 34.81%
Avg. Price $81.92 $86.96 $82.56 $94.38 $98.61 $92.78
P/E Ratio 13.32 12.6 12.12 13.09 13.24 9.22
Free Cash Flow (M) $1,233 $1,322 $1,435 $1,399 $1,394 $1,433
CAPEX (M) $45 $42 $42 $38 $28 $50
Total Debt (M) $1,672 $1,657 $1,923 $2,176 $2,243 $2,116
Current Ratio 0.39 0.25 0.37 0.19 0.21 0.21
The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.

IN FOCUS